{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:20:47Z","timestamp":1790011247582,"version":"4.0.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2002,10]]},"abstract":"<jats:p>\n            This study investigated the process of nitric oxide (NO) release from platelets after stimulation with different angiotensin II type 1 (AT\n            <jats:sub>1<\/jats:sub>\n            )-receptor antagonists and its effect on platelet adhesion and aggregation. Angiotensin II AT\n            <jats:sub>1<\/jats:sub>\n            -receptor antagonist\u2013stimulated NO release in platelets was compared with that in human umbilical vein endothelial cells by using a highly sensitive porphyrinic microsensor. In vitro and ex vivo effects of angiotensin II AT\n            <jats:sub>1<\/jats:sub>\n            -receptor antagonists on platelet adhesion to collagen and thromboxane A\n            <jats:sub>2<\/jats:sub>\n            analog U46619-induced aggregation were evaluated. Losartan, EXP3174, and valsartan alone caused NO release from platelets and endothelial cells in a dose-dependent manner in the range of 0.01 to 100 \u03bcmol\/L, which was attenuated by NO synthase inhibitor N\n            <jats:sup>G<\/jats:sup>\n            -nitro-\n            <jats:sc>l<\/jats:sc>\n            -arginine methyl ester. The angiotensin II AT\n            <jats:sub>1<\/jats:sub>\n            -receptor antagonists had more than 70% greater potency in NO release in platelets than in endothelial cells. The degree of inhibition of platelet adhesion (collagen-stimulated) and aggregation (U46619-stimulated) elicited by losartan, EXP3174, and valsartan, either in vitro or ex vivo, closely correlated with the NO levels produced by each of these drugs alone. The inhibiting effects of angiotensin II AT\n            <jats:sub>1<\/jats:sub>\n            -receptor antagonists on collagen-stimulated adhesion and U46619-stimulated aggregation of platelets were significantly reduced by pretreatment with N\n            <jats:sup>G<\/jats:sup>\n            -nitro-\n            <jats:sc>l<\/jats:sc>\n            -arginine methyl ester. Neither the AT\n            <jats:sub>2<\/jats:sub>\n            receptor antagonist PD123319, the cyclooxygenase synthase inhibitor indomethacin, nor the selective thromboxane A\n            <jats:sub>2<\/jats:sub>\n            \/prostaglandin H\n            <jats:sub>2<\/jats:sub>\n            receptor antagonist SQ29,548 had any effect on angiotensin II AT\n            <jats:sub>1<\/jats:sub>\n            -receptor antagonist\u2013stimulated NO release in platelets and endothelial cells. The presented studies clearly indicate a crucial role of NO in the arterial antithrombotic effects of angiotensin II AT\n            <jats:sub>1<\/jats:sub>\n            -receptor antagonists.\n          <\/jats:p>","DOI":"10.1161\/01.hyp.0000034745.98129.ec","type":"journal-article","created":{"date-parts":[[2002,10,3]],"date-time":"2002-10-03T22:24:58Z","timestamp":1033683898000},"page":"521-527","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":113,"title":["Angiotensin II AT\n            <sub>1<\/sub>\n            Receptor Antagonists Inhibit Platelet Adhesion and Aggregation by Nitric Oxide Release"],"prefix":"10.1161","volume":"40","author":[{"given":"Leszek","family":"Kalinowski","sequence":"first","affiliation":[{"name":"From the Department of Chemistry and Biochemistry, Ohio University (L.K., T. Malinski), Athens, Ohio; Department of Laboratory Medicine, Medical University of Gdansk, and the Laboratory of Cellular and Molecular Nephrology, Medical Research Center of the Polish Academy of Science (L.K.), Gdansk; and the Department of Pharmacodynamics, Medical Academy of Bialystok (T. Matys, E.C., W.B.), Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Matys","sequence":"additional","affiliation":[{"name":"From the Department of Chemistry and Biochemistry, Ohio University (L.K., T. Malinski), Athens, Ohio; Department of Laboratory Medicine, Medical University of Gdansk, and the Laboratory of Cellular and Molecular Nephrology, Medical Research Center of the Polish Academy of Science (L.K.), Gdansk; and the Department of Pharmacodynamics, Medical Academy of Bialystok (T. Matys, E.C., W.B.), Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Chabielska","sequence":"additional","affiliation":[{"name":"From the Department of Chemistry and Biochemistry, Ohio University (L.K., T. Malinski), Athens, Ohio; Department of Laboratory Medicine, Medical University of Gdansk, and the Laboratory of Cellular and Molecular Nephrology, Medical Research Center of the Polish Academy of Science (L.K.), Gdansk; and the Department of Pharmacodynamics, Medical Academy of Bialystok (T. Matys, E.C., W.B.), Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W\u0142odzimierz","family":"Buczko","sequence":"additional","affiliation":[{"name":"From the Department of Chemistry and Biochemistry, Ohio University (L.K., T. Malinski), Athens, Ohio; Department of Laboratory Medicine, Medical University of Gdansk, and the Laboratory of Cellular and Molecular Nephrology, Medical Research Center of the Polish Academy of Science (L.K.), Gdansk; and the Department of Pharmacodynamics, Medical Academy of Bialystok (T. Matys, E.C., W.B.), Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeusz","family":"Malinski","sequence":"additional","affiliation":[{"name":"From the Department of Chemistry and Biochemistry, Ohio University (L.K., T. Malinski), Athens, Ohio; Department of Laboratory Medicine, Medical University of Gdansk, and the Laboratory of Cellular and Molecular Nephrology, Medical Research Center of the Polish Academy of Science (L.K.), Gdansk; and the Department of Pharmacodynamics, Medical Academy of Bialystok (T. Matys, E.C., W.B.), Poland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2001.00800.x"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1646156"},{"key":"e_1_3_2_3_2","first-page":"25","volume":"57","year":"1999","unstructured":"Riddell DR, Owen JS. Nitric oxide and platelet aggregation. Vitam Horm. 1999; 57: 25\u201348.","journal-title":"Vitam Horm"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.34.2.285"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64523-3"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200011010-00007"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1050-1738(96)00091-6"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199808000-00005"},{"key":"e_1_3_2_9_2","first-page":"238","volume":"292","year":"2000","unstructured":"Li P, Fukuhara M, Diz DI, Ferrario CM, Brosnihan KB. Novel angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in canine coronary arteries and human platelet aggregation. J Pharmacol Exp Ther. 2000; 292: 238\u201346.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200006000-00012"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.9.4888"},{"key":"e_1_3_2_12_2","first-page":"595","volume":"262","year":"1992","unstructured":"Ohlstein EH, Gellai M, Brooks DP, Vickery L, Jugus J, Sulpizio A, Ruffolo RR Jr, Weinstock J, Edwards RM. The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism. J Pharmacol Exp Ther. 1992; 262: 595\u2013601.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.26.2.236"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.28.3.397"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199715120-00072"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199911000-00016"},{"key":"e_1_3_2_17_2","first-page":"705","volume":"51","year":"2000","unstructured":"Matys T, Chabielska E, Pawlak R, Kucharewicz I, Buczko W. Losartan inhibits the adhesion of rat platelets to fibrillar collagen: a potential role of nitric oxide and prostanoids. J Physiol Pharmacol. 2000; 51: 705\u2013713.","journal-title":"J Physiol Pharmacol"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/358676a0"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1993.1914"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.105.8.933"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119540"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(88)90474-8"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.28.6.967"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/4.3.228"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200106000-00009"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/hyp.37.1.34"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199511000-00003"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.56"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/res.88.8.756"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.HYP.0000034745.98129.EC","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T16:18:12Z","timestamp":1715530692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.HYP.0000034745.98129.EC"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["10.1161\/01.HYP.0000034745.98129.EC"],"URL":"https:\/\/doi.org\/10.1161\/01.hyp.0000034745.98129.ec","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10]]},"assertion":[{"value":"2002-04-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-08-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-09-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}